Who is sponsoring NCT03304470?

NCT03304470 is sponsored by UNION therapeutics.

What condition does NCT03304470 study?

NCT03304470 studies Atopic Dermatitis.

What drugs are being tested in NCT03304470?

Interventions: ATx201 2% Cream, ATx201 Cream Vehicle.

What is the status of NCT03304470?

NCT03304470 is currently COMPLETED.

Last reviewed 2018-03-20 · How we verify

A Study to Evaluate the Safety and Efficacy of ATx201 in Subjects With Moderate Atopic Dermatitis

NCT03304470 PHASE2 COMPLETED

This is a Phase 2, 3-week, single-center, double-blind, randomized, two-arm, vehicle controlled study, with each individual receiving both active and vehicle treatment. Approximately 30 subjects with moderate atopic dermatitis will receive topically applied ATx201 CREAM 2% and matching vehicle once daily for 3 weeks (5 mg/cm2/day), without occlusion. ATx201 and vehicle will be applied on two separate target lesions of moderate atopic dermatitis (lesions of at least 3 × 3 cm, excluding the face, scalp, genitals, hands, and feet, ideally from the same anatomical location).

Details

Lead sponsor	UNION therapeutics
Phase	PHASE2
Status	COMPLETED
Enrolment	31
Start date	Mon Sep 25 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Mon Mar 05 2018 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Atopic Dermatitis

Interventions

ATx201 2% Cream
ATx201 Cream Vehicle

Countries

Canada